跳至主要内容
临床试验/ISRCTN93391015
ISRCTN93391015已完成不适用

A randomised, double-blind, placebo-controlled, two-sequence, two-period, crossover study to evaluate the effect of SMP-028 on oral contraceptive pharmacokinetics in healthy female subjects

Dainippon Sumitomo Pharma Europe Ltd (UK)0 个研究点目标入组 22 人开始时间: 2010年1月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
22

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Healthy female subjects aged 18 to 45 years
  • 2. In good health as determined by:
  • 2.1. Past medical history
  • 2.2. Physical examination
  • 2.3. Electrocardiogram
  • 2.4. Clinical safety laboratory tests
  • 2.5. Urinalysis

排除标准

  • 1. Contraindications to the administration of a combined oral contraceptive (OC) pill
  • 2. Other standard exclusion criteria

研究者

发起方
Dainippon Sumitomo Pharma Europe Ltd (UK)

相似试验

招募中
1 期
A two-part study to investigate the effects in adults of two doses of a new drug called golexanolone in patients with primary biliary cholangitis with fatigue and cognitive dysfunctio
EUCTR2022-000422-16-GRmecrine Cognition AB101
进行中(未招募)
1 期
A two-part study to investigate the effects in adults of two doses of a new drug called golexanolone in patients with primary biliary cholangitis with fatigue and cognitive dysfunctioPrimary biliary cholangitis (PBC)MedDRA version: 20.0Level: SOCClassification code 10019805Term: Hepatobiliary disordersSystem Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2022-000422-16-HUmecrine Cognition AB101
招募中
1 期
A two-part study to investigate the effects in adults of two doses of a new drug called golexanolone in patients with primary biliary cholangitis with fatigue and cognitive dysfunctio
EUCTR2022-000422-16-ESmecrine Cognition AB101
进行中(未招募)
不适用
A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson?s disease - A study to assess the effect of safinamide on levodopa pharmacokineticsMedDRA version: 9.1Level: LLTClassification code 10013113Parkinson Disease
EUCTR2008-002769-30-ITMERCK SERONO SA
进行中(未招募)
2 期
A two-part study to assess the effectiveness, safety, and blood levels of repeat doses of inhaled ETD001 in people with cystic fibrosisRespiratoryCystic Fibrosis
ISRCTN11798668Enterprise Therapeutics Ltd35